<DOC>
	<DOC>NCT02890966</DOC>
	<brief_summary>The objective of the study is to assess the tolerance, pharmacokinetic and pharmacodynamic properties of multiple dose adminstration of SHR4640 in healthy volunteers.</brief_summary>
	<brief_title>Multiple Dose Study of SHR4640 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>1. Age between 18 and 55, male; 2. Body weight≥50, BMI:1925kg/m2; 3.4 mg/dL≤Screening serum urate level≤7 mg/dL; 4.Medically stable based on physical examination, laboratory results, vital sign measurements, 12lead electrocardiogram, abdomen Bultrasound and Chest Xray examination at screening. 1. Serum creatinine＞upper limits of normal(ULN); 2. Alanine aminotransferase and/or Aspartate aminotransferase＞2×ULN, total bilirubin＞1.5×ULN, glutamyltransferase＞3×ULN; 3. History of hyperuricemia or gout; 4. History or suspicion of kidney stones; 5. Positive results for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, syphilis antibody test.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>SHR4640 pharmacokinetics pharmacodynamics</keyword>
</DOC>